PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models.
- Resource Type
- Article
- Authors
- Berlin, Michael; Cantley, Jennifer; Bookbinder, Mark; Bortolon, Elizabeth; Broccatelli, Fabio; Cadelina, Greg; Chan, Emily W.; Chen, Huifen; Chen, Xin; Cheng, Yunxing; Cheung, Tommy K.; Davenport, Kim; DiNicola, Dean; Gordon, Debbie; Hamman, Brian D.; Harbin, Alicia; Haskell, Roy; He, Mingtao; Hole, Alison J.; Januario, Thomas
- Source
- Journal of Medicinal Chemistry; 1/25/2024, Vol. 67 Issue 2, p1262-1313, 52p
- Subject
- Language
- ISSN
- 00222623